Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Coherus Oncology, Inc.NASDAQ: CHRS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $23.1M fell 11.2% year over year, ahead of the -30.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.1% from the prior quarter. Over 3 fiscal years it compounded at -20.7% a year.

Context

  • Selling, general & admin amounted to 234.8% of revenue in FY2025, up 178.4 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $58.09M (-41.3%) for the fiscal year ending Dec 2026, a slowdown from the -34.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.1M-2.1% QoQ
Last fiscal yearDec 2025
$99M-34.2% YoY
LTMMar 2026
$95.58M-30.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.2%-43.6%-32.4 pp
1 year-34.2%-41.3%-7.1 pp
3-year CAGR-20.7%+11.0%+31.7 pp
5-year CAGR+27.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
99M USD
Year-over-year change
-34.2%
4-year CAGR
-12.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 selling, general & admin of $95.58M is the highest of the 11 companies compared; the peer median is $25.33M.
  • Its year-over-year change of -30.3% is the lowest of 11, against a peer median of +9.3%.
  • Selling, general & admin amounts to 203.9% of revenue for CHRS, versus a peer median of 95.1%.
CHRS Competitors Peer median
Selling, General & Admin for CHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$95.58M -30.3%-20.7%203.9%
IVVDInvivyd, Inc.LTM Mar 2026$74.78M +14.7%+12.5%133.9%
CDXSCodexis, Inc.LTM Mar 2026$43.75M -19.9%-3.4%56.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M -16.4%-5.4%98.7%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$31.65M -26.4%-17.7%91.6%
OABIOmniAb, Inc.LTM Mar 2026$26.47M -12.7%+5.5%91.6%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M +23.5%+3.4%41000.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$23.01M +25.6%+1.9%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.81M +22.1%-7.6%914.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$16.29M +45.3%-0.9%—
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$12.13M +3.8%-0.1%15.9%
Peer median (excluding CHRS) $25.33M+9.3%-0.5%95.1%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.